Le Lézard
Classified in: Health
Subjects: PDT, SLS

Successful Dr.FORHAIR's Hair Loss Shampoo Launch Leads to Renewed 1-Year U.S. Costco Contract


Global Scalp Solutions Brand's First U.S. Costco Launch of Folligen Original Shampoo Met With Outstanding Sales

LOS ANGELES, March 27, 2024 /PRNewswire/ -- Dr.FORHAIR, a global scalp care brand sold 18,000 units of Folligen Original Shampoo at 50 U.S. locations within just 3 weeks of its first offline launch of the product. After successfully being sold online to the U.S. market, this clinically-proven hair loss prevention shampoo was launched in stores on October, 2023 across 50 American Costco branches. This award-winning shampoo was sold in Florida, New York, Hawaii, New Jersey, with a heavy focus on California. The explosive success for the brand's first U.S. in-store launch acts as a swift segue into a renewed 1-year contract with Costco beginning on June, 2024 in 250 Costco branches.

Dr.FORHAIR

"The root of why our product is well-loved by consumers is the deep trust and confidence that they have for our brand. Over the years, we've honed superior quality, outstanding value, and earned our consumers' trust as a result," said Phillip Kwon, Vice President at Wyatt Corp.

Dr.FORHAIR has led the scalp solutions market in Korea with its focus on clinical evidence that has repeatedly resulted in high customer satisfaction. Customers have long since raved about the hair loss prevention shampoo, with a 99.9% satisfaction rate for improvements in odor and oily scalp (a result of sebum), forelock and side hair volume, and cleanliness.

Along with preventing hair loss, the Folligen Original Shampoo offers clinically proven scalp solutions, lowering excess sebum and dead skin cells while boasting anti-aging effects in just 4 weeks, like boosting elasticity, silkiness, shine, and moisture. It has received an excellent rating for the skin stability test by Global Dermatology Research Institute's Dermatest, showing it to be free of silicon oil, sulfates, and surfactant parabens as well as being hypoallergenic and color safe. This mild, safe, and effective formula has consequently made it a crowd favorite among customers, with scalp changes being reported after just 1 use.

After a successful launch, Dr.FORHAIR looks to gain more attention for its award-winning hair loss prevention shampoo. The two-pack of 750ml Folligen Original Shampoo bottles will be made available in Costco once again this month. "We've worked hard to exceed consumer expectations, and we're excited to connect with more consumers with Costco as a new avenue of communicating our product," said Phillip Kwon, Vice President at Wyatt Corp.

About Dr.FORHAIR: Dr.FORHAIR is a global scalp care brand by Wyatt Corp with Scalp Labs based in New York and Seoul. Using comprehensive clinical research and industry expertise, the brand provides a variety of scalp care products that helps millions of customers worldwide.

Website: https://www.drforhair.com/

Media Contact

Jiwoo Lee, [email protected]

SOURCE Dr.FORHAIR


These press releases may also interest you

at 20:11
Report with the AI impact on market trends - The global online therapy services market size is estimated to grow by USD 64.09 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of  53.9%  during the forecast...

at 20:02
BioVaxys Technology Corp. (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce, further to its news release of January 10, 2025, an extension of its previously announced non-brokered private placement offering of units of the Company (the...

at 19:25
The new year brings new beginnings for 26Health and its patients with the grand opening of a newly renovated facility in Orlando. "We...

at 19:00
CG Pharmaceuticals (CG Pharma), a clinical biopharmaceutical company located in the San Francisco Bay Area, was established as an independent entity in 2024 after licensing ivaltinostat from CG Invites. The company has since been conducting various...

at 18:00
Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell-targeting Alluminoxtm platform-based photoimmunotherapy, today announced the initiation of its global multi-regional Phase 3 clinical trial...

at 17:46
Andlauer Healthcare Group Inc. ("AHG" or the "Company") will release its 2024 fourth quarter and year-end financial results after market close on Wednesday, February 26, 2025. Michael Andlauer, Chief Executive Officer, and Peter Bromley, Chief...



News published on and distributed by: